New antibody drug for blood cancers tested in first human trial
Disease control
Terminated
This was a very early (phase 1) study testing a new antibody drug called ESG206 in people with advanced B-cell blood cancers that had stopped responding to other treatments. The main goal was to check safety and find the right dose. However, the study was withdrawn before any par…
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:27 UTC